Maximizing the outcome of early ADMET models: Strategies to win the drug-hunting battles?

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 4, 2011, Pages 381-386

  Wang, Jianling ^a   Collis, Alan ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

absorption; ADMET; distribution; DMPK; elimination; ISIVIVC; metabolism; toxicity

Indexed keywords

ALGORITHM; COMPUTER MODEL; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MODEL; NONHUMAN; OUTCOME ASSESSMENT; PROCESS OPTIMIZATION; REVIEW;

ABSORPTION; BIOLOGICAL AVAILABILITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG TOXICITY; HUMANS; METABOLIC DETOXICATION, DRUG; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 79952935246     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2011.562199     Document Type: Review

References (29)

1. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25 (Pubitemid 27046991)
2. Kerns EH, Di L. Pharmaceutical profiling in drug discovery. Drug Discov Today 2003;8(7):316-23 (Pubitemid 36332223)
3. Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol 2007;3(5):641-65 (Pubitemid 351320635)
4. Kennedy T. Managing the drug discovery/development interface. Drug Discov Tech 1997;2:436-41
5. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711-15 (Pubitemid 39173511)
6. Wang J. Comprehensive assessment of ADMET risks in drug discovery. Curr Pharm Des 2009;15(19):2195-219
7. Caldwell GW, Yan Z, Tang W, et al. ADME optimization and toxicity assessment in early-and late-phase drug discovery. Curr Top Med Chem 2009;9(11):965-80
8. Wan H, Holmen AG. High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb Chem High Throughput Screen 2009;12(3):315-29
9. Youdim KA, Zayed A, Dickins M, et al. Application of CYP3A4 in vitro data to predict clinical drug-drug interactions; predictions of compounds as objects of interaction. Br J Clin Pharmacol 2008;65(5):680-92 (Pubitemid 351535079)
10. Perdaems N, Blasco H, Vinson C, et al. Predictions of metabolic drug-drug interactions using physiologically based modelling: two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 2010;49(4):239-58
11. Lombardo F, Obach RS, Waters NJ. Plasma protein binding and volume of distribution: determination, prediction and use in early drug discovery. Methods Princ Med Chem 2009;43:197-220
12. Heimbach T, Lakshminarayana SB, Hu W, et al. Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. AAPS J 2009;11(3):602-14
13. Wang J, Skolnik S. Mitigating permeability-mediated risks in drug discovery. Expert Opin Drug Metab Toxicol 2010;6(2):171-87
14. Ekins S, Honeycutt JD, Metz JT. Evolving molecules using multi-objective optimization: applying to ADME/Tox. Drug Discov Today 2010;15:451-60
15. Hamon J, Whitebread S, Techer-Etienne V, et al. In vitro safety pharmacology profiling: what else beyond hERG? Future Med Chem 2009;1(4):645-65
16. Zhou H. Lead optimization in the non drug-like space. Drug Discov Today 2011;16(3/4):158-63
17. Egan WJ, Merz KM Jr, Baldwin JJ. Prediction of drug absorption using multivariate statistics. J Med Chem 2000;43:3867-77
18. Gabrielsson J, Dolgos H, ran Gillberg P-G, et al. Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations. Drug Discov Today 2009;14(7/8):358-72
19. Cavero I. Using pharmacokinetic/pharmacodynamic modelling in safety pharmacology to better define safety margins: a regional workshop of the Safety Pharmacology Society. Expert Opin Drug Saf 2007;6(4):465-71 (Pubitemid 351308175)
20. Wager TT, Chandrasekaran RY, Hou X, et al. Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010;1(6):420-34
21. De Buck SS, Sinha VK, Fenu LA, et al. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 2007;35(10):1766-80 (Pubitemid 47481568)
22. Jamei M, Marciniak S, Feng K, et al. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009;5(2):211-23
23. Maguire TJ, Novik E, Chao P, et al. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr Drug Metab 2009;10(10):1192-9
24. Sung JH, Esch MB, Shuler ML. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling. Expert Opin Drug Metab Toxicol 2010;6(9):1063-81
25. Swift B, Pfeifer ND, Brouwer KLR. Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 2010;42(3):446-71
26. Biswas D, Roy S, Sen S. A simple approach for indexing the oral druglikeness of a compound: discriminating druglike compounds from nondruglike ones. J Chem Inform Mod 2006;46(3):1394-401 (Pubitemid 43999183)
27. Obach RS, Kalgutkar AS, Soglia JR, et al. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 2008;21(9):1814-22
28. Hou T, Wang J. Structure -ADME relationship: still a long way to go? Expert Opin Drug Metab Toxicol 2008;4(6):759-70 (Pubitemid 352003198)
29. Wang J, Skolnik S. Recent advances in physicochemical and ADMET profiling in drug discovery. Chem Biodivers 2009;6:1887-99